Acute megakaryoblastic leukemia in children and adolescents, excluding Down's syndrome: improved outcome with intensified induction treatment
2005
Abstract
In summary, AMKL remains an AML subgroup with a pooroutcome in spite of all available treatment options. Intensification of induction treatment as scheduled in the AML-BFM studies resulted in an improved prognosis compared to historical control.
AlloSCT revealed no additional benefit. Further research is necessary to develop new and better treatment options to improve prognosis in these children.